Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1958 1
1959 1
1960 1
1961 5
1963 2
1964 1
1965 2
1966 2
1968 3
1969 5
1970 7
1971 5
1972 2
1973 3
1974 8
1975 7
1976 3
1977 13
1978 12
1979 5
1980 6
1981 9
1982 12
1983 14
1984 19
1985 15
1986 34
1987 25
1988 22
1989 38
1990 42
1991 39
1992 21
1993 26
1994 28
1995 29
1996 39
1997 36
1998 39
1999 38
2000 49
2001 50
2002 62
2003 70
2004 78
2005 85
2006 68
2007 75
2008 77
2009 78
2010 70
2011 78
2012 88
2013 98
2014 93
2015 94
2016 96
2017 110
2018 85
2019 93
2020 88
2021 109
2022 103
2023 7
Text availability
Article attribute
Article type
Publication date

Search Results

2,323 results
Results by year
Filters applied: . Clear all
Page 1
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells.
Taniguchi H, Yamada T, Wang R, Tanimura K, Adachi Y, Nishiyama A, Tanimoto A, Takeuchi S, Araujo LH, Boroni M, Yoshimura A, Shiotsu S, Matsumoto I, Watanabe S, Kikuchi T, Miura S, Tanaka H, Kitazaki T, Yamaguchi H, Mukae H, Uchino J, Uehara H, Takayama K, Yano S. Taniguchi H, et al. Among authors: yano s. Nat Commun. 2019 Jan 16;10(1):259. doi: 10.1038/s41467-018-08074-0. Nat Commun. 2019. PMID: 30651547 Free PMC article.
Treatment of Retinoblastoma 1-Intact Hepatocellular Carcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination Therapy.
Sheng J, Kohno S, Okada N, Okahashi N, Teranishi K, Matsuda F, Shimizu H, Linn P, Nagatani N, Yamamura M, Harada K, Horike SI, Inoue H, Yano S, Kumar S, Kitajima S, Ajioka I, Takahashi C. Sheng J, et al. Among authors: yano s. Hepatology. 2021 Oct;74(4):1971-1993. doi: 10.1002/hep.31872. Epub 2021 Aug 25. Hepatology. 2021. PMID: 33931882
Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer.
Nanjo S, Wu W, Karachaliou N, Blakely CM, Suzuki J, Chou YT, Ali SM, Kerr DL, Olivas VR, Shue J, Rotow J, Mayekar MK, Haderk F, Chatterjee N, Urisman A, Yeo JC, Skanderup AJ, Tan AC, Tam WL, Arrieta O, Hosomichi K, Nishiyama A, Yano S, Kirichok Y, Tan DS, Rosell R, Okimoto RA, Bivona TG. Nanjo S, et al. Among authors: yano s. J Clin Invest. 2022 Jul 1;132(13):e145099. doi: 10.1172/JCI145099. J Clin Invest. 2022. PMID: 35579943 Free PMC article.
A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer.
Yasuda H, Ichihara E, Sakakibara-Konishi J, Zenke Y, Takeuchi S, Morise M, Hotta K, Sato M, Matsumoto S, Tanimoto A, Matsuzawa R, Kiura K, Takashima Y, Yano S, Koyama J, Fukushima T, Hamamoto J, Terai H, Ikemura S, Takemura R, Goto K, Soejima K. Yasuda H, et al. Among authors: yano s. Lung Cancer. 2021 Dec;162:140-146. doi: 10.1016/j.lungcan.2021.10.006. Epub 2021 Oct 16. Lung Cancer. 2021. PMID: 34808485 Clinical Trial.
In Reply.
Arai S, Yano S. Arai S, et al. Among authors: yano s. J Thorac Oncol. 2020 Jun;15(6):e93. doi: 10.1016/j.jtho.2020.03.010. J Thorac Oncol. 2020. PMID: 32471570 Free article. No abstract available.
Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer.
Wang R, Yamada T, Kita K, Taniguchi H, Arai S, Fukuda K, Terashima M, Ishimura A, Nishiyama A, Tanimoto A, Takeuchi S, Ohtsubo K, Yamashita K, Yamano T, Yoshimura A, Takayama K, Kaira K, Taniguchi Y, Atagi S, Uehara H, Hanayama R, Matsumoto I, Han X, Matsumoto K, Wang W, Suzuki T, Yano S. Wang R, et al. Among authors: yano s. Nat Commun. 2020 Sep 14;11(1):4607. doi: 10.1038/s41467-020-18442-4. Nat Commun. 2020. PMID: 32929081 Free PMC article.
Does body height affect vascular function?
Yano S. Yano S. Hypertens Res. 2022 Feb;45(2):369-371. doi: 10.1038/s41440-021-00812-0. Epub 2021 Dec 7. Hypertens Res. 2022. PMID: 34876696 No abstract available.
Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL.
Kameda K, Kako S, Kim SW, Usui Y, Kato K, Fukuda T, Uchida N, Kobayashi H, Wakayama T, Sakaida E, Yano S, Imada K, Nara M, Ikeda T, Fuchida SI, Ishikawa J, Sugahara H, Kanda J, Kimura T, Ichinohe T, Atsuta Y, Kondo E. Kameda K, et al. Among authors: yano s. Leukemia. 2022 May;36(5):1361-1370. doi: 10.1038/s41375-022-01545-w. Epub 2022 Mar 28. Leukemia. 2022. PMID: 35347237
2,323 results